MBD

PR

엠비디 홍보자료 및 게시판

    Biochip Platform Could Enable Personalized Immunotherapy
  • MBD 
  • 08-27 
  • 120 
    August 25, 2021 | Rensselaer Polytechnic Institute and South Korean biotech Medical & Bio Decision Company Ltd. (MBD) are working on turning a biochip into a personalized immunotherapy platform for rapidly screening a wide range of treatment cocktails for individual cancer patients. The platform would be ideally suited for very small tumor biopsy samples, including those extracted by fine needle aspiration, to see how well different combinations of chemotherapeutic drugs and monoclonal antibodies work in concert with natural killer (NK) cells in the tumor microenvironment, according to Jonathan Dordick, professor of chemical and biological engineering at Rensselaer.